Telix Pharmaceuticals Ltd. has agreed to acquire ITM Isotope Technologies Munich SE for up to $2.35 billion, seeking greater ...
Positive allosteric modulators (PAMs) of muscarinic acetylcholine M1 receptor are being developed to address cognitive deficits in Alzheimer’s disease, schizophrenia and other neuropsychiatric ...
Shanghai Curegene Pharmaceutical Co. Ltd. has disclosed influenza virus neuraminidase (sialidase) inhibitors and their liposome formulations reported to be useful for the treatment of influenza A and ...
New therapeutic strategies against P. aeruginosa are urgently needed. Polyclonal antibodies (pAbs) may provide broader coverage than mAbs by recognizing multiple bacterial epitopes and reducing immune ...
Parkinson’s disease (PD) is driven not only by dopamine loss but also by neurodegenerative processes linked to iron dysregulation and ferroptosis in the substantia nigra. Researchers from Zhejiang ...
A gene therapy for treating X-linked retinitis pigmentosa is edging closer to approval, with Beacon Therapeutics Ltd. reporting positive results from the pivotal phase II/III trial of laruparetigene ...
NACHT, LRR and PYD domains-containing protein 3 (NLRP3) is a sensor of cellular damage and stress in immune cells, thus being an interesting target for inflammatory diseases, such as Alzheimer’s (AD) ...
Maze Therapeutics Inc. has synthesized sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors potentially useful for the treatment of phenylketonuria, metabolic syndrome and ...
As Amgen Inc.’s Imdelltra (tarlatamab) pushes into the first-line setting for small-cell lung cancer, a fast-growing field of DLL3-directed T-cell engagers, antibody-drug conjugates and cell therapies ...
Total biopharma financings through August 2026 reached $77.13 billion for the year, closely matching 2024's $77.52 billion ...
Faeth Therapeutics Inc. recently reported the development and preclinical evaluation of FTX-249, a selective inhibitor of 4-hydroxyphenylpyruvate dioxygenase (HPPD) designed to address the various ...
A year after launching with a $65 million series A investment, Dualitas Therapeutics Inc. has signed up its first partner, Roche Holding AG, to use its Dualscreen Bispecific Discovery Engine to screen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results